Mycoach isn’t a demo. It’s embedded in clinical practice today — and the proof is in the publications, the trials, and the depth of disease coverage it already supports.
Figures are platform-reported aggregates across deployed sites, as of 2026.
The fastest way to judge a clinical data platform is to ask what came out of it. From Mycoach: peer-reviewed science, multi-center trials, and competitive research funding — all drawn from structured real-world data.
Impact factors up to 66.8 and 650+ cumulative citations, co-authored with clinical partners.
The platform serves as the structured-data backbone across its hospital network.
Studies built on the platform have attracted national and provincial research grants since 2021.
In production across neurology, cardiology, oncology, rheumatology and more.
We go vertical before we go wide. Our anchor is neuromuscular disease — where continuous, quantified tracking matters most, and where we built a first-of-its-kind assessment.
A first-of-its-kind AI assessment of disease severity (QMG), bringing objective, quantified tracking out of the clinic.
Coverage extends across motor-neuron and inherited neuromuscular conditions that demand longitudinal data.
The same structured foundation extends into new specialties through existing hospital partnerships.
The myasthenia gravis multi-center registry home: a 3,048-case cohort with enrollment, completeness and follow-up tracking (de-identified demo view, Chinese UI).
The dual-wheel claim on our homepage rests on 2 kinds of third-party sources: peer-reviewed studies of research-active hospitals, and industry analyses of patient-retention economics. None of these are our measurements; read them directly.
External links open in a new tab. Third-party sources are cited for context; they are not Mycoach measurements.
Pick a 30 minute slot, or write to us and bring a sample workflow.